Table 2. Sensitivity analysis of data from the subgroup of patients.
| Characteristics | Ruptured IA (n = 310)* | Unruptured IA (n = 610)* | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | |||
| Age, y (SD) | 63.2 (16.0) | 62.5 (10.2) | 1.00 | 0.99–1.02 | 0.44 | |||
| Women, n (%) | 219 (70.7) | 410 (67.2) | 1.17 | 0.87–1.58 | 0.29 | |||
| Smokers, n (%) | 139 (44.8) | 288 (47.2) | 0.91 | 0.69–1.20 | 0.49 | |||
| History of aSAH, n (%) | 11 (3.6) | 35 (5.7) | 0.60 | 0.30–1.21 | 0.15 | 0.65 | 0.27–0.30 | 0.27 |
| Familial history of aSAH, n (%) | 39 (12.6) | 157 (25.7) | 0.42 | 0.28–0.61 | < 0.0001 | 0.44 | 0.29–0.66 | < 0.0001 |
| Size, mm (SD) | 7.0 (3.9) | 5.5 (2.1) | 1.19 | 1.13–1.26 | < 0.0001 | 1.22 | 1.15–1.29 | < 0.0001 |
| Calcium channel blockers | 63 (20.3) | 235 (38.5) | 0.41 | 0.30–0.56 | < 0.0001 | 0.41 | 0.29–0.60 | < 0.0001 |
| Angiotensin II receptor blockers | 73 (23.6) | 225 (36.9) | 0.53 | 0.39–0.72 | < 0.0001 | 0.66 | 0.46–0.95 | 0.02 |
| Angiotensin-converting enzyme inhibitors | 8 (2.6) | 23 (3.8) | 0.68 | 0.30–1.53 | 0.34 | - | - | - |
| Renin inhibitors | 1 (0.3) | 1 (0.2) | 1.97 | 0.12–31.6 | 1.00 | - | - | - |
| Thiazide/Indapamide | 12 (3.9) | 38 (6.2) | 0.61 | 0.31–1.18 | 0.14 | 0.84 | 0.40–1.79 | 0.66 |
| β-adrenergic receptor blockers | 24 (7.7) | 51 (8.4) | 0.92 | 0.55–1.53 | 0.75 | - | - | - |
| HMG-CoA reductase inhibitors (statins) | 50 (16.1) | 177 (29.0) | 0.47 | 0.33–0.67 | < 0.0001 | 0.61 | 0.41–0.90 | 0.01 |
| Eicosapentaenoic acid | 8 (2.6) | 18 (3.0) | 0.87 | 0.37–2.03 | 0.75 | - | - | - |
| Dipeptidyl peptidase-4 inhibitors | 9 (2.9) | 29 (4.8) | 0.6 | 0.28–1.28 | 0.18 | 0.86 | 0.38–1.95 | 0.71 |
| Peroxisome proliferator-activated receptor γ agonists | 2 (0.7) | 6 (1.0) | 0.65 | 0.13–3.26 | 0.72 | - | - | - |
| Biguanides | 4 (1.3) | 15 (2.5) | 0.52 | 0.17–1.58 | 0.24 | - | - | - |
| Selective serotonin reuptake inhibitors | 5 (1.6) | 8 (1.3) | 1.23 | 0.40–3.80 | 0.77 | - | - | - |
| Glucocorticoids | 10 (3.2) | 9 (1.5) | 2.23 | 0.89–5.54 | 0.08 | 2.51 | 0.87–7.28 | 0.09 |
| Non-aspirin non-steroidal anti-inflammatory drugs | 24 (7.7) | 20 (3.3) | 2.48 | 1.35–4.56 | 0.003 | 2.48 | 1.26–4.90 | 0.009 |
| Selective COX-2 inhibitors | 8 (2.6) | 11 (1.8) | 1.44 | 0.57–3.62 | 0.43 | - | - | - |
| Selective estrogen receptor modulators | 1 (0.3) | 9 (1.5) | 0.22 | 0.03–1.71 | 0.18 | 0.14 | 0.02–1.24 | 0.08 |
| Anticoagulants | 6 (1.9) | 11 (1.8) | 1.07 | 0.39–2.93 | 0.89 | - | - | - |
| Aspirin | 17 (5.5) | 59 (9.7) | 0.54 | 0.31–0.95 | 0.03 | 0.78 | 0.42–1.47 | 0.45 |
| Anti-platelet agents | 13 (4.2) | 27 (4.4) | 0.95 | 0.48–1.86 | 0.87 | - | - | - |
*Data are shown as the n (%) and mean (SD).
Abbreviations; CI = confidence interval, IA = intracranial aneurysm, OR = odds ratio, SD = standard deviation, aSAH = aneurysmal subarachnoid hemorrhage, HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A, COX = cyclooxygenase.
Aspirin and other anti-platelet agents are additionally included in the sensitivity analysis.